Drug Profile
SP 20202
Alternative Names: SP20202Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Sarfez Pharmaceuticals
- Class Heart failure therapies; Urologics
- Mechanism of Action Mineralocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetic nephropathies
- Discontinued Heart failure
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for clinical-Phase-Unknown development in Diabetic-nephropathies in USA
- 24 Nov 2017 Clinical trials in Diabetic nephropathies in USA before November 2017 (Sarfez pipeline, November 2017)
- 24 Nov 2017 Discontinued - Preclinical for Heart failure in USA (Sarfez pipeline, November 2017)